CLDN18 and colorectal carcinoma: In the study, we used the same immunohistochemical antibody and cutoff criteria and demonstrated that CLDN18 expression was seen in 27% of colitis-associated colorectal carcinomas with an association of MUC5AC expression, while without significant association with MUC6 status [23].